![](https://worldnewsradar.id/wp-content/uploads/2025/08/BANNER-RENT-300X47-COLUMN-1.png"){kind=small}
Amid escalating trade tensions, the European pharmaceutical industry is calling for calm as fears grow over a potential wave of U.S. tariffs targeting drug imports. Industry leaders have urged the European Union not to retaliate if former President Donald Trump follows through on his recent threat to impose tariffs on pharmaceuticals. With a self-imposed deadline for finalizing new trade deals fast approaching, concerns are rising that the U.S. could act as early as next week. The call for restraint highlights the fragile dynamics of transatlantic trade talks and the potential risk to both global healthcare and diplomatic relations.
I. Rising Tensions Between the U.S. and EU
1. Trump’s Tariff Warning Sparks Alarm
Former President Donald Trump recently suggested that new, sector-specific tariffs could be introduced “very soon,” specifically targeting pharmaceutical imports. As his July 9 deadline for completing trade agreements with the European Union and dozens of other countries looms, speculation is growing that these measures could be a bargaining tactic aimed at gaining leverage.
European officials are now grappling with whether to prepare countermeasures or seek a more conciliatory approach to avoid escalating a trade war that could damage healthcare systems and economies on both sides of the Atlantic.
2. Industry Urges Brussels to Avoid Retaliation
Stefan Oelrich, president of the European Federation of Pharmaceutical Industries and Associations (EFPIA), voiced his concerns during a press briefing in Brussels. He warned that retaliatory tariffs from the EU would have a mutually damaging effect.
“We’re exporting a significant volume of products from the U.S. to Europe. If tariffs are introduced, the impact would be negative for everyone,” he said. “Reciprocating with import duties would be the wrong move—it’s just a flawed concept.”
II. Fragile Trade Talks and Political Dynamics
1. A Narrow Trade Deal on the Horizon
As negotiations continue, there is growing consensus that a limited agreement focusing on sectors like automobiles and steel may be the most realistic outcome. Such a deal would echo the bilateral pact negotiated by UK Prime Minister Keir Starmer, which is set to take effect shortly.
However, pharmaceutical industry leaders remain pessimistic about their sector being included in any finalized deal. Despite their global importance, medicines and healthcare products appear to be sidelined in trade discussions.
2. Key EU Member States Push for Pragmatic Agreement
Germany and France are among the EU nations pushing for a swift trade agreement with the U.S., hoping to avoid drawn-out negotiations. German Chancellor Friedrich Merz advocated for a “quick and simple” resolution, while French President Emmanuel Macron emphasized the need for a fair and pragmatic deal.
Meanwhile, smaller EU states—especially those in the Baltic region—are encouraging warm ties with the U.S., particularly after Trump’s perceived victory at the recent NATO summit over increased defense commitments. These countries see closer alignment with the U.S. as critical to maintaining American support for Ukraine.
III. Pharma Industry’s Broader Challenges in Europe
1. Europe’s Declining Role in Drug Innovation
Oelrich, who also serves as a board member at German pharmaceutical giant Bayer, highlighted the need for systemic reforms in the EU to regain its competitive edge in drug research and development. He emphasized that Europe is rapidly losing ground to the U.S. and China in the creation of new medications.
According to 2023 data, China outpaced the EU by launching 25 new active pharmaceutical ingredients, compared to just 17 from the EU and 28 from the U.S. This trend signals a worrisome shift in innovation leadership, and Oelrich warns that regulatory fragmentation and restrictive pricing policies are contributing factors.
2. Non-Tariff Barriers Stalling Market Access
Oelrich pointed out that approximately 25% of drugs approved by the U.S. Food and Drug Administration (FDA) over the last decade have not been made available in Europe. He attributed this gap largely to non-tariff obstacles such as inconsistent national regulations and pricing strategies across EU member states.
“Many biotech firms see no value in entering the European market—it simply doesn’t make economic sense,” Oelrich noted.
IV. Burdensome Pricing Policies and Market Disincentives
1. Clawback Mechanisms Undermining Innovation
Among the problematic practices Oelrich highlighted is the use of “clawbacks,” where governments, particularly in larger markets like France and the UK, impose fixed budgets for specific medications. Any consumption exceeding the pre-agreed budget is absorbed by pharmaceutical companies, creating financial uncertainty.
“It’s irrational and counterproductive,” he said. “This practice is widespread across Europe and must be reconsidered.”
Such policies, while designed to contain public healthcare costs, are creating long-term deterrents for pharma investment and innovation within the continent.
2. Price Benchmarking Between High- and Low-Income Nations
Another issue is the European trend of aligning medicine prices in wealthier nations with those in lower-income member states. Oelrich warned that this race to the bottom results in unsustainable pricing models.
“The wealthiest countries trying to match the lowest available prices leads to outcomes that are financially unviable,” he stated. This environment diminishes incentives for pharmaceutical firms to launch or even consider Europe as a viable market.
Conclusion: A Call for Reform and Strategic Patience
The European pharmaceutical industry stands at a crossroads. On one side, it faces the immediate threat of U.S. tariffs that could disrupt supply chains and raise the cost of care for patients. On the other, it is contending with deep-rooted policy and regulatory challenges that are eroding its competitive position in global healthcare innovation.
While calls for the EU to resist retaliatory action are centered on avoiding further harm, the broader message is a plea for structural change. To revitalize its role as a leader in drug development, the EU must harmonize its regulations, reconsider damaging pricing strategies, and foster a more attractive environment for research and market entry.
As the deadline for potential U.S. trade action approaches, the EU has a chance to demonstrate strategic patience and long-term vision—ensuring that short-term political responses do not compromise access to life-saving medicines or the future of European innovation.
